Explore the structural impact of posttranslational modifications, chemical synthesis strategies, and their impact on novel drug design in this informative webinar.
Posttranslational modifications regulate the location, interactions and destruction of a protein, controlling fundamental cellular processes that are highly relevant in novel drug modality design.
However, unravelling the precise effects of these modifications on proteins is challenging because of difficulties in obtaining proteins bearing site-specific modifications for structural and functional studies. Furthermore, the impact of posttranslational modifications on protein structure is seldom investigated, leaving a gap in the knowledge of how posttranslational modifications modulate protein function.
In this webinar, assistant professor Dr. Anne Conibear from the Technical University of Vienna (TU Wien) will present her work toward understanding the structural effects of posttranslational modifications in intrinsically disordered proteins.
In the first part, she will demonstrate how solid-phase peptide synthesis provides access to modified peptides for structural studies and how protein semi-synthesis tools can generate site-specifically modified and segmentally isotope-labelled proteins for nuclear magnetic resonance (NMR) spectroscopy. Her studies reveal how integrating chemical protein synthesis with structural biology allows scientists to gain new insights into the impact of protein posttranslational modifications on protein structure, dynamics and regulation.
Luísa Aguiar, Field Application Specialist from Gyros Protein Technologies, will join the second part of the webinar, where they will take attendees on a more hands-on and practical session to some of the considerations of synthesizing peptides with posttranslational modifications, including technical strategies such as optimized amino acid deliveries on automated synthesizers, as well as ongoing challenges for an open discussion with the audience.
Don’t miss this chance to learn about the latest research in posttranslational protein modifications and a unique opportunity to obtain technical insights to synthesize these challenging peptides.
Join this exciting webinar about leveraging the chemical synthesis of posttranslationally modified peptides to study proteins using state-of-the-art peptide technology.
Dr. Anne C. Conibear, Assistant Professor, Institute of Applied Synthetic Chemistry, TU Wien (Technical University of Vienna)
Dr. Anne Conibear completed her BSc (Hons) and MSc in Chemistry (2010) at Rhodes University in South Africa. She then moved to the University of Queensland, Australia for her PhD (2014) with Prof. David Craik, focusing on the structural characterization and applications of cyclic disulfide-rich peptides from mammals, the theta-defensins. In 2014, she was awarded an Interdisciplinary cancer research postdoctoral fellowship at the University of Vienna and worked with Prof. Christian Becker on targeted immune-stimulating molecules for cancer therapy, collaborating with Syntab Therapeutics GmbH. She returned to the University of Queensland in 2019 with a UQ Development fellowship to study the synthesis and structure of posttranslationally modified proteins. At the start of 2022, she took up a tenure-track Assistant Professor position in protein chemistry at TU Wien.
Dr. Luisa Aguiar, Field Application Specialist, Gyros Protein Technologies
Dr. Luísa Aguiar received her chemistry degree in 2012, having carried out both her graduation and master thesis at the Faculty of Sciences of the University of Porto. She pursued her doctoral thesis devoted to the synthesis and evaluation of novel peptide-drug conjugates with potential interest against neglected tropical diseases. Luísa concluded her PhD in April of 2019 and worked as a Post-doctoral Research Fellow at Paula Gomes’s Lab before joining Gyros Protein Technologies in 2021 as a Field Application Specialist.
Who Should Attend?
This webinar will appeal to:
- Scientists, Senior Scientists, technical leaders or Researchers interested in peptide or protein chemistry
- PhD candidates, Post-doctoral Researchers
- Researchers involved in peptide therapeutics or peptide synthesis
What You Will Learn
Attendees will gain insights into:
- How posttranslational modifications regulate the structures and biological roles of proteins
- Strategies for accessing proteins with site-specific posttranslational modifications for structural and biochemical experiments
- Considerations and approaches to manual and automated synthesis of modified peptides
- Practical strategies for addressing some of the challenges of synthesizing difficult sequences
Gyros Protein Technologies
Gyros Protein Technologies enables peptide and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the PurePep(r) Chorus, Symphony(r) X, and PurePep(r)Sonata(r)+. The PurePep(r) EasyClean (PEC) technology complements the PurePep(r) portfolio with Kits and Services for peptide purification and modification.
These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides up- and downstream. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab(r) xPand, Gyrolab(r) xP workstation and Gyrolab xPlore(tm), are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is part of the Biopharmaceutical Division of Mesa Laboratories, Inc.